Table 1 Patient characteristics in clinical trials
1st author | Study | Number of patients | Median age (range) | Therapy (%) | Diagnosis | del 11q22.3 (%) | del 17p13.1 (%) | CYP3A45 strong inhibitors | ||
|---|---|---|---|---|---|---|---|---|---|---|
Front-line | Relapse | CLL (%) | SLL (%) | |||||||
Byrd et al. | RESONATE | 195 | 67 (30–86) | 0 | 100 | 95 | 5 | 32 | 32 | Excluded |
Burger et al. [3] | RESONATE-2 | 136 | 73 (65–89) | 100 | 0 | 90 | 10 | 21 | 0 | Excluded |
O’Brien et al. [5] | RESONATE-17 | 144 | 64 (57–72) | 0 | 100 | 95 | 5 | 16 | 100 | Excluded |
Ahn et al. [6] | NCT01500733 | 86 | 66 (33–85) | 61.6 | 38.4 | 1 | 0 | NR | 58 | NR |
Byrd et al. [25] | PCYC 1102 phase 1b/2 (NEJM 2013) | 85 | 68 (37–82) | 0 | 100 | 96 | 4 | 36 | 33 | NR |
O’Brien et al. [24] | PCYC 1102 phase 1b/2 (Lancet 2014) | 31 | 71 (65–84) | 100 | 0 | 94 | 6 | 3 | 6 | NR |
Byrd et al. [26] | PCYC 1103 3-year FU (Blood 2015) | 132 | 68 (37–84) | 23 | 77 | 96 | 4 | 27 | 27 | Avoided |
Coutre et al. [4] | PCYC 1103 44-month FU | 94 | 68 (37–84) | 29 | 71 | NR | NR | 23 | 27 | Avoided |
Chen et al. [27] | NCT02801578 | 11 | 68 (52–79) | NR | NR | 100 | 0 | 0 | 0 | NR |